Ignite Creation Date:
2024-05-06 @ 10:59 AM
Last Modification Date:
2024-10-26 @ 12:38 PM
Study NCT ID:
NCT03407859
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2017-04-09
Brief Title:
Sequential Treatment With CD20CD22CD10-CART After CD19-CART Treatment Base on MRD in RelapsedRefractory B-ALL
Sponsor:
Zhujiang Hospital
Organization:
Zhujiang Hospital
Study Overview
Official Title:
Sequential Treatment With CD20CD22CD10-CART After CD19-CART Treatment Base on MRD in RelapsedRefractory B-ALL
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients CD20CD22CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19-negative relapse of B-ALL Thus sequential treatment with CD20CD22CD10-CART after CD19-CART treatment in relapsedrefractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time
Detailed Description:
B-cell acute lymphoblastic leukemia is the most common type of leukemia and the prognosis of relapsedrefractory B-ALL is poor Chimeric Antigen Receptor-transduced T cell CAR-T therapy is one of revolutionary targeted immunotherapy CD19 CAR-T is the most commonly used engineered T cell in B-ALL The treatment effect is significant and far more than traditional therapy in relapsedrefractory B-ALL However the remission time after CD19 CAR-T infusion is shortCD19-positive and CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients The cause of relapse after CAR-T infusion is minimal residual disease MRD which will induce CD19 negative relapse CD20CD22CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19 negative relapse of B-ALL Thus sequential treatment with CD20CD22CD10-CART after CD19-CART treatment in relapsedrefractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None